A big leap in total revenues is a sign AstraZeneca is well on its way to hitting its goal of $80bn by 2030.
If it keeps growing at this rate itโll break through the $100bn threshold instead.
The real driver is its exceptionally strong pipeline, with 2025 bringing Phase III data for seven new medicines.
Thereโs no guarantee any of these will make it through but itโs clear the company is doing something right in the R&D division. Spending has really ramped up since 2019 and has produced a wave of drug candidates and treatments, especially in oncology, and which should power revenue growth if thereโs a steady trickle of approvals over the next few years.
Revenues are growing at a healthy clip in practically all areas apart from China, which AZN puts down to low rates of seasonal respiratory viral infections. There was little reference to the recent legal headlines in the East though.
Shares took a hit late in 2024 after the head of the companyโs Chinese business was detained and there was only a passing mention of it today.
China only comprises 13% of the groupโs top line but itโs the prospect of a hefty fine thatโs weighing on investorsโ confidence. AZN might not be able to say anything but the longer it rumbles on, the more uncomfortable the market will become.
Leave a Comment